$APVO News

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".

APVO: Focusing on Three Key Areas of Development

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors